Treatment of Lower Extremity Superficial Thrombophlebitis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30383173.
- Also identified by DOI 10.1001/jama.2018.16623.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Which treatments for lower extremity superficial thrombophlebitis (ST) are associated with lower rates of venous thromboembolic events (VTEs) vs placebo? A dose of 2.5 mg of fondaparinux administered subcutaneously once daily for 45 days is associated with fewer cases of symptomatic VTE without an increase in major bleeding vs placebo. Low-molecular-weight heparin (LMWH) and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with lower rates of ST extension or recurrence vs placebo, but data regarding symptomatic VTE remain inconclusive. Oral rivaroxaban requires further evaluation.
Medical subject headings
- Anticoagulants
- Thrombophlebitis
- Venous Thromboembolism